Navigation Links
TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
Date:7/6/2012

SUNNYVALE, Calif., July 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that its President & CEO Gerald E. Commissiong was interviewed by TheStockRadio.com following Amarantus' recent presentation at the National Investment Banking Association conference. To listen to the full in-depth interview, please visit http://thestockradio.com/gerald-e-commissiong-ceo-of-amarantus-biosciences-inc-otcambs/1081.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS: Amarantus BioSciences, Inc. Gerald E. Commissiong 408.737.2734 x 102 pr@amarantus.com

 

 


'/>"/>
SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ion Proton™ Sequencer - Inventor, Dr. M. Jonathan Rothberg and Life Technologies CEO, Greg Lucier, Available for Interviews at CES Today
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
4. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
5. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
6. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
7. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
8. Entia Biosciences Receives Patent for Use of Ergothioneine in Foods and Beverages
9. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
10. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
11. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2019)... ... December 18, 2019 , ... Tune in to CNBC on Saturday, December 28th ... local listings for more information on this program. , With a look at ... simplify complex system to increase the efficiency, safety and effectiveness of equipment, systems, and ...
(Date:12/6/2019)... ... December 06, 2019 , ... Southern ... for its latest CAPERE® Thrombectomy System for peripheral vascular, deep vein thrombosis ... benefits for first-in-line treatment for nonsurgical removal of soft emboli and thrombi ...
(Date:12/4/2019)... ... December 03, 2019 , ... Absolute Antibody Ltd. , ... with the Recombinant Antibody Network (RAN), a consortium of three expert centers at ... a common goal to generate recombinant antibodies at a proteome-wide scale. Under the ...
(Date:12/4/2019)... ... December 03, 2019 , ... A new study released ... can reduce and even reverse fibrosis (scar tissue) buildup – also improves the range ... School of Medicine, was conducted on mice. , The tumor-destroying capabilities of radiation ...
Breaking Biology Technology:
(Date:12/14/2019)... , ... December 12, 2019 , ... ... that protect or enhance crop yields, has appointed Jean Pougnier as chief business ... establish relationships with go-to-market partners and influencers that will position the company for ...
(Date:12/2/2019)... ... December 01, 2019 , ... ... tools, technologies, and techniques to hit the life-science landscape. For more than a ... speeding work in laboratories and facilitating biological discovery. This year’s crop of entries ...
(Date:11/22/2019)... BUFFALO, N.Y. (PRWEB) , ... November 21, 2019 ... ... immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step ... and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell ...
Breaking Biology News(10 mins):